Scarica l'app Stockscreener
36.30
0.96%
0.345
Dopo l'orario di chiusura:
36.31
0.005
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO) - PrimePublishers.com
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events - ADVFN
BridgeBio: Early Signs Point To Blockbuster Revenues - Seeking Alpha
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET | BBIO Stock News - GuruFocus
BridgeBio Pharma, Inc. to Report First Quarter Financial Results and Program Updates on April 29, 2025 - Nasdaq
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET - TradingView
BridgeBio Sets Q1 2025 Earnings Call: Key Genetic Disease Pipeline Updates Expected April 29 - Stock Titan
BridgeBio Pharma director Ellis sells $350,000 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma director Ellis sells $350,000 in stock - Investing.com Australia
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
BridgeBio (BBIO) Receives Increased Price Target from H.C. Wainw - GuruFocus
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BBIO Stock News - GuruFocus
BridgeBio Pharma (BBIO) Sees Promising Growth Amid Market Volati - GuruFocus
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Expands Team: Strategic Equity Grants Awarded to 20 New Hires - Stock Titan
Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Praxis Precision Medicines (PRAX) - The Globe and Mail
BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock By Investing.com - Investing.com Canada
BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock - Investing.com India
Redburn Atlantic Initiates Coverage of BridgeBio Pharma (MUN:2CL) with Buy Recommendation - Nasdaq
Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada
Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire
Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa
Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq
BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener
Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM - Yahoo Finance
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - MarketScreener
Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India
Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Breakthrough: New ATTR-CM Drug Shows Dramatic 59% Risk Reduction in Phase 3 Trial - Stock Titan
Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus
Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
(BBIO) Technical Data - news.stocktradersdaily.com
Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN
BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada
BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India
Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
BridgeBio’s Beyonttra approved in Japan - The Pharma Letter
BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com
BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq
Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - MarketScreener
Japan approves new ATTR-CM treatment Beyonttra - Investing.com
Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times
BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq
Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN
BridgeBio Pharma Inc (BBIO) Announces Equity Grants to New Employees - GuruFocus.com
Bridgebio Pharma reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:05 pm EDT - Marketscreener.com
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):